Amarna Therapeutics

Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of both rare and prevalent diseases. The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naive. Amarna has created a proprietary production cell line (SuperVeroTM) that, for the first time, makes it possible to produce SV40-derived vectors suitable for therapeutic use. Combining SuperVeroTM with its genetically engineered SVec viral vector, the companys fully-integrated gene therapy platform is truly unique in its intrinsic capability to deliver transgenes without eliciting immune responses to the vector nor to the transgene product. Leveraging this natural non-immunogenicity feature of its gene delivery system in humans, Amarna is developing a broad pipeline of safe, effective and durable gene therapies focused on genetic disorders, a...